CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

A visual look at Wall Street's Santa Claus rallies since 2000, even as such a rally comes under pressure on Thursday. Read ...

Gap is on the rise, with strong Q3 results signaling a turnaround. It trades at just 11.9x fwd P/E, well below the industry ...

Trainline is capitalizing on the digitization of rail travel with a 17% sales increase. See why we recommend a buy rating on ...

Nokian grew underlying earnings regardless prior to the rapid production ramp-up. Its Romanian factory will start production ...

Green Dot is poised for growth with strong FCF yield and market positions, but faces risks from retail declines and customer ...

Mueller Water Products is a strong long-term investment with its innovative water products, strong financial performance, and ...

Stock futures declined after a quiet post-holiday session on Friday, with jobless claims data minimally impacting Fed's outlook. Trading activity may remain subdued later today due to lack of major US ...

Leggett & Platt's vertical integration and restructuring plans are expected to enhance operating margins and free cash flow ...

Green Brick's Q3 2024 revenues were $523 million, which is a 25.7% increase YoY. It offers the possibility of buying a solid ...

Melco Resorts' Q324 shows improvement. Substantial debt and upcoming maturities pose significant financial risks. Read an ...

TFLO is a top choice for reliable income investing, offering stability and above-average yields in uncertain market ...